A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapy

dc.contributor.author Politi, Angeliki Louiza
dc.date.accessioned 2021-03-19T15:05:49Z
dc.date.available 2021-03-19T15:05:49Z
dc.date.issued 2021
dc.description Master in Health Economics and Pharmacoeconomics (UPF Barcelona School of Management) Curs 2018-2021ca
dc.description Mentor: Carlos Crespo
dc.description.abstract The purpose of this study is to conclude as to whether it is cost-effective to introduce genotyping in the Norwegian clinical practice in the case of acute coronary syndrome, as a guide of pharmacotherapy decision making after a percutaneous coronary intervention.ca
dc.format.mimetype application/pdf*
dc.identifier.uri http://hdl.handle.net/10230/46867
dc.language eng
dc.language.iso engca
dc.rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licenseca
dc.rights.accessRights info:eu-repo/semantics/openAccessca
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/ca
dc.subject.other Treball de fi de màster – Curs 2020-2021ca
dc.subject.other Clopidogrelca
dc.subject.other Ticagrelorca
dc.subject.other Percuntaneous coronary interventionca
dc.subject.other economic evaluationca
dc.subject.other cost.effectivenessca
dc.subject.other CYPca
dc.subject.other antiplateletsca
dc.title A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapyca
dc.type info:eu-repo/semantics/masterThesisca

Col·leccions